Mass Drug Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis
The American Journal of Tropical Medicine and Hygiene · 02.04.2024 · 110 (4_Suppl) · 17-29
DOI: 10.4269/ajtmh.22-0766 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, erschienen am 02.04.2024. Verfasst von Zachary D Schneider und 6 weiteren Autor:innen. Beteiligte Einrichtung: Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia. Hauptthemen laut MEDLINE: Antimalarials, Mass Drug Administration, Malaria, Falciparum, Malaria, Vivax. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
Malaria remains a significant cause of morbidity and mortality, even in low-transmission settings. With the advent of longer acting, more effective, and well-tolerated antimalarials, there is renewed interest in the efficacy of mass drug administration (MDA) to accelerate to elimination. We conducted a systematic review and meta-analysis to assess the efficacy of MDA to reduce the incidence and prevalence of Plasmodium falciparum ( Pf ) and Plasmodium vivax ( Pv ) infection. From 1,044 articles screened, 14 articles, including 10 randomized controlled trials (RCTs), were identified. Five included data on Pf only; five included Pf and Pv . Two of the Pf studies were conducted in areas of high–moderate transmission, the remainder were in areas of low–very low transmission. In higher transmission areas, MDA reduced incidence of Pf parasitemia (rate ratio = 0.61, 95% CI: 0.40–0.92; moderate certainty) 1 to 3 months after drug administration; no significant effect of MDA on Pf parasitemia prevalence was detected 1 to 3 months post-MDA (risk ratio [RR] = 1.76, 95% CI: 0.58–5.36; low certainty). In lower transmission settings, both incidence and prevalence of Pf parasitemia were reduced 1 to 3 months post-MDA (rate ratio = 0.37, 95% CI: 0.21–0.66; RR = 0.25, 95% CI: 0.15–0.41, respectively). Pv prevalence was reduced 1 to 3 months post-MDA (RR = 0.15, 95% CI: 0.10–0.24); there were no RCTs providing data on incidence of Pv . There was no significant effect of MDA at later time points. MDA may have short-term benefits; however, there was no evidence for longer term impact, although none of the trials assessed prolonged interventions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Rollins School of Public Health, Emory University, Atlanta, Georgia.
- U.S. President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia.
- Global Malaria Programme, World Health Organization, Geneva, Switzerland.
Förderung
- World Health Organization
Zitieren
APA
Schneider, Z. D., Shah, M. P., Boily, M. C., Busbee, A. L., Hwang, J., Lindblade, K. A., & Gutman, J. R. (2024). Mass Drug Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis. The American Journal of Tropical Medicine and Hygiene, 110(4_Suppl), 17-29. https://doi.org/10.4269/ajtmh.22-0766
Vancouver
Schneider ZD, Shah MP, Boily MC, Busbee AL, Hwang J, Lindblade KA, et al. Mass Drug Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis. The American Journal of Tropical Medicine and Hygiene. 2024;110(4_Suppl):17-29. doi:10.4269/ajtmh.22-0766
BibTeX
@article{Schneider2024,
author = {Schneider, Zachary D and Shah, Monica P and Boily, Marisa C and Busbee, Alexandra L and Hwang, Jimee and Lindblade, Kim A and Gutman, Julie R},
title = {Mass Drug Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2024},
volume = {110},
number = {4_Suppl},
pages = {17--29},
doi = {10.4269/ajtmh.22-0766}
}
EUVIMED